Rationale of Cancer Immunotherapy targets
Vaxeal target selection was based on expression and tumour cell vital functions. Survivin and Cyclin B1 are undetectable or transiently expressed in most normal adult tissues.
They are both over-expressed in most human cancers, and play vital functions in tumor cells. Both targets are associated with a poor prognosis.
Rationale of Long Synthetic Peptides
Long peptides are vaccines able to generate strong and sustainable specific CD4+ and CD8+ T-cell responses in humans, irrespective of individual Human Leukocyte Antigen (HLA) types. In addition, Long Synthetic Peptides (LSPs) have the strong advantage to be safe and easy to manufacture compared to “biological vaccines” created from living organisms. The efficacy of the cancer immunotherapies is further increased by their formulation with new adjuvants, and fixed combination with antibodies that modulate tumour-induced immune suppression (Immune Checkpoint Blockades).
Rationale of fixed combination with Immune Checkpoint Blockades (ICBs)
Fixed combination of therapeutic vaccines with ICBs have the potential to increase clinical efficacy of cancer: Induction of specific and long-lasting anti-tumoral CD4+ and CD8+ T-cell responses; Block immune checkpoint pathways suppressing the anti-tumoral immune response in the tumor microenvironment.